Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 17/20 | 0.70 |
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033809 | 0.82 | PYCR1 (1.00) | PYCR1MAOBLMNAUSP2CYP3A4 | |
| SCHEMBL8244727 | 0.82 | PYCR1 (0.72) | PYCR1MAOBLMNAUSP2CYP3A4 | |
| SCHEMBL9416592 | 0.81 | BCHE (0.53) | MAOBMAOAALDH1A1ACHE | |
| SCHEMBL5680713 | 0.81 | PYCR1 (0.70) | PYCR1MAOBLMNAUSP2CYP3A4 | |
| Pargyline SCHEMBL18036659 | 0.80 | PYCR1 (1.00) | PYCR1MAOBLMNAUSP2CYP3A4 | |
| Pargyline SCHEMBL2045 | 0.80 | PYCR1 (1.00) | PYCR1MAOBLMNAUSP2CYP3A4 | |
| SCHEMBL10033801 | 0.79 | PYCR1 (0.79) | PYCR1MAOBLMNAUSP2CYP3A4 | |
| Pargyline SCHEMBL7363311 | 0.78 | PYCR1 (0.96) | PYCR1MAOBLMNAUSP2CYP3A4 | |
| Pargyline SCHEMBL121111 | 0.78 | LMNA (1.00) | PYCR1MAOBLMNAUSP2CYP3A4 | |
| SCHEMBL29235425 | 0.78 | PYCR1 (1.00) | PYCR1MAOBLMNAUSP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539078-B | Active small molecular probe for specifically sorting monoamine oxidase, preparation method and application thereof | 南京工业大学 | 2023-04-07 | — | — | CN | claimed |
| CN-114539078-A | Active small molecular probe for specifically sorting monoamine oxidase, preparation method and application thereof | 南京工业大学 | 2022-05-27 | — | — | CN | claimed |
| CN-114544571-B | Method for constructing bioorthogonal reaction base paper device and application of bioorthogonal reaction base paper device in monoamine oxidase detection | 南京工业大学 | 2023-04-18 | — | — | CN | disclosed |
| CN-114539078-B | Active small molecular probe for specifically sorting monoamine oxidase, preparation method and application thereof | 南京工业大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-114544571-A | Method for constructing bioorthogonal reaction base paper device and application of bioorthogonal reaction base paper device in monoamine oxidase detection | 南京工业大学 | 2022-05-27 | — | — | CN | disclosed |
| CN-114539078-A | Active small molecular probe for specifically sorting monoamine oxidase, preparation method and application thereof | 南京工业大学 | 2022-05-27 | — | — | CN | disclosed |
| US-8124802-B2 | e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance | JENRIN DISCOVERY, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124802-B2 | e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance | JENRIN DISCOVERY, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| WO-2008092091-A2 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008092091-A2 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | MAOA, MAOB, PNMT | PYCR1 975/4885MAOB 2/4885LMNA 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.